Correspondence | Published:

Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Leukemia volume 31, pages 771772 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.

  2. 2.

    , , , , , et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.

  3. 3.

    , , , , , et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.

  4. 4.

    , , , , , et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89: 732–742.

  5. 5.

    , , , , , et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014; 124: 3135.

  6. 6.

    , , , , , et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.

  7. 7.

    , , , , , et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.

  8. 8.

    , , , , , et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013; 42 (9 Pt 2): e303–e310.

Download references

Acknowledgements

The authors thank Nathalie Ross, Science and Medical Writer, funded by Novartis Pharmaceuticals for contributing to the writing and editing of this Correspondence. Novartis had no influence on the content of this document.

Author information

Affiliations

  1. Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada

    • C Constance
  2. Department of Medicine, Université de Montréal, Montreal, QC, Canada

    • C Constance
  3. Division of Internal Medicine, Jewish General Hospital, Montreal, QC, Canada

    • L Trudeau
  4. Montreal Heart Institute, Montreal, QC, Canada

    • E M Jolicoeur
  5. Center for Pulmonary Vascular Disease and Division of Cardiology, Jewish General Hospital, Montreal, QC, Canada

    • D Langleben
  6. Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada

    • A Rivard
  7. Centre intégré de cancérologie de la Montérégie, Hôpital Charles-LeMoyne, Quebec, QC, Canada

    • R Chehayeb
  8. CHU de Québec - Hôpital du Saint-Sacrement, Greenfield Park, QC, Canada

    • M-A Côté
  9. University Health Network, Toronto, ON, Canada

    • D Delgado

Authors

  1. Search for C Constance in:

  2. Search for L Trudeau in:

  3. Search for E M Jolicoeur in:

  4. Search for D Langleben in:

  5. Search for A Rivard in:

  6. Search for R Chehayeb in:

  7. Search for M-A Côté in:

  8. Search for D Delgado in:

Competing interests

Dr Christian Constance has received honorarium and support for clinical trials from Astra, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Dr David Langleben has received honoraria and support for clinical trials from Actelio, Bayer, Eiger Biophamaceuticals, Ikaria, Northern Therapeutics, Novartis and United Therapeutics. He has served on advisory boards for Actelion, Bayer, Ikaria, Northern Therapeutics, Novartis, UCB Celltech and United Therapeutics. The remaining authors declare no conflict of interest.

Corresponding author

Correspondence to C Constance.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/leu.2016.336

Further reading